Overview of the Class
This class groups together peptides and related compounds commonly discussed in the context of growth hormone (GH) signaling, GH secretagogues, and downstream growth-factor biology. Examples include GHRH analogs (e.g., sermorelin), ghrelin receptor agonists / GHRPs, GH analogs, and IGF-related research peptides.
In many cases, public discussion moves faster than formal clinical evidence. Regulatory status, product quality, and anti-doping status may vary widely across molecules.
Mechanism of Action (Class Themes)
Mechanistic themes vary by molecule, but often include one or more of the following:
- Stimulating endogenous GH release via hypothalamic/pituitary signaling (GHRH analogs) or via ghrelin receptor pathways (GHRPs)
- Delivering GH activity directly (GH analogs) rather than stimulating secretion
- Targeting downstream growth pathways (IGF and growth-factor signaling) in experimental models
These pathways are physiologically potent and can affect multiple organ systems. Interpreting claims requires attention to endpoints, dosing, and the difference between short-term biomarkers and long-term outcomes.
Safety and Side Effects (Class Themes)
Safety considerations depend heavily on the exact molecule and whether it is an approved medicine. Common discussion themes include dose-related side effects, metabolic changes, injection-site issues, and the risk of inappropriate use outside regulated indications.
For research peptides, additional uncertainty is introduced by manufacturing variability and the absence of robust pharmacovigilance.
Research and Evidence Themes
Evidence in this space ranges from physiology and biomarker work to preclinical studies and (for some regulated medicines) larger human datasets. A few secretagogues have completed formal development — tesamorelin, for example, is an approved medicine labeled for the reduction of excess abdominal fat in HIV-infected adults with lipodystrophy. Many other compounds in this space — IGF-related fragments and most research-grade secretagogues — rest mainly on early-stage or preclinical work.
Entries in this Class (22)
Frequently Asked Questions
How do GH secretagogues differ from GH analogs?
Secretagogues (GHRH analogs like sermorelin, and ghrelin-pathway agents like the GHRPs) prompt the pituitary to release its own growth hormone, so output stays partly under the body’s feedback control. GH analogs deliver growth hormone activity directly, bypassing that regulation. The distinction matters for pulsatility, feedback effects, and how each type is studied and regulated.
Why does anti-doping status dominate discussions of this class?
Growth hormone, its releasing factors, and secretagogues are broadly prohibited in sport, and detection methods continue to improve. For athletes subject to testing, that prohibition applies regardless of a compound’s evidence base or regulatory status.
What kinds of evidence exist across this class?
It ranges widely. Prescription growth hormone has decades of clinical data in its approved deficiency indications, while many research-grade secretagogues rest mainly on early-stage or preclinical work, so evidence must be assessed molecule by molecule.
Evidence tier: Approved medicine · Last reviewed: 2026-09-05 · Sources cited below.